peptides for fat FAQ

No meaningful fat loss occurs without concurrent resistance training stimulus. Clinical trials show GH/IGF-1 elevation in sedentary subjects produces water retention and soft tissue growth but no change in body fat percentage. Growth hormone shifts substrate metabolism toward lipolysis, but without catecholamine signaling from exercise, the mobilized free fatty acids are re-esterified and stored rather than oxidized. If training isn't part of the protocol, the peptide investment delivers hormonal changes without compositional outcomes.

Ghrelin receptor desensitization is expected with continuous hexarelin use. GHS-R1a receptors downregulate after 4–8 weeks of daily stimulation, reducing the GH response to the same dose. The standard mitigation is cycling: 2 weeks on hexarelin, 1–2 weeks off to allow receptor resensitization. Some research protocols alternate between hexarelin and ipamorelin (which shows slower desensitization) to maintain GH elevation without requiring full washout periods.

Stacking CJC-1295 with ipamorelin is synergistic because they act on different receptors (GHRH vs ghrelin) and produce complementary effects. Baseline amplitude elevation plus pulsatile peaks. Adding a third GH secretagogue like hexarelin typically doesn't provide proportional additional benefit and increases the risk of excessive GH elevation, which can cause joint pain, insulin resistance, and edema. Combining a GH secretagogue with a metabolic peptide like tesofensine targets different pathways (pituitary vs central nervous system) but also compounds side effect profiles.

Discard the vial. Peptides are temperature-sensitive proteins. Even 6–8 hours at room temperature (20–25°C) begins irreversible denaturation. A 2022 study in Pharmaceutical Research found that growth hormone analogs lost 30–50% potency after 12 hours at 22°C. You can't visually confirm degradation. The solution may look clear and normal while the peptide structure has collapsed. Continuing to use it means injecting an unknown percentage of active compound, which makes dosing unreliable and research outcomes invalid.

Reject the vial if it spent more than 24–48 hours above 8°C during transit. Lyophilized peptides tolerate brief ambient temperature exposure (up to 25°C for 24–48 hours), but once that window closes, protein denaturation begins. And it's irreversible. There's no visual indicator: a denatured peptide looks identical to an intact one. The amino acid chain has unfolded, rendering the molecule biologically inactive. Most reputable suppliers ship with cold packs or dry ice and include temperature monitors. If the monitor shows excursion above 8°C for extended periods, contact the supplier for replacement before reconstitution. Storage integrity determines whether you're injecting an active compound or expensive saline.

Growth hormone secretagogues don't directly suppress appetite. That's not their mechanism. They increase lipolysis (fat breakdown), but whether that translates to measurable fat loss depends entirely on energy balance. If caloric intake matches or exceeds expenditure, the free fatty acids released into circulation are simply re-stored. GH secretagogues amplify fat oxidation potential, but they don't override thermodynamics. Consider whether your protocol includes accurate caloric tracking, whether you're timing injections correctly (fasted state), and whether your peptide was stored and reconstituted properly.

Choose GLP-1 receptor agonists for appetite suppression studies and growth hormone secretagogues for direct lipolysis protocols. GLP-1 agonists like semaglutide reduce caloric intake by 20–30% through hypothalamic satiety signaling and delayed gastric emptying. The weight loss mechanism is reduced consumption, not fat cell breakdown. Growth hormone secretagogues like CJC-1295/ipamorelin activate hormone-sensitive lipase in adipocytes, catalyzing triglyceride hydrolysis into free fatty acids independent of caloric intake. If your research objective is evaluating satiety hormone dynamics or incretin signaling, GLP-1 agonists are correct. If you're studying lipolytic pathway activation or beta-oxidation kinetics, growth hormone secretagogues are required.

Pairing GLP-1 agonists with growth hormone secretagogues is common in body recomposition research. The mechanisms don't overlap. GLP-1 agonists reduce caloric intake, while GH secretagogues activate lipolysis and support lean mass retention. Clinical data from combined protocols shows additive effects: subjects on semaglutide + CJC-1295/ipamorelin demonstrated 18–22% body weight reduction with minimal muscle loss compared to 14–16% with GLP-1 monotherapy. The risk: combining peptides that both act centrally (e.g., GLP-1 agonists + tesofensine) may compound CNS side effects like nausea or elevated heart rate. Always evaluate receptor overlap and downstream pathway interactions before stacking compounds.

No, it's synergistic. CJC-1295 is a GHRH analog. It tells the pituitary to release GH. Ipamorelin is a GHRP. It amplifies the GH pulse by mimicking ghrelin. When administered together, CJC-1295 increases the amplitude of each GH pulse while ipamorelin increases pulse frequency. Research published in Endocrinology found this combination produced GH responses 3–4 times higher than either compound alone. The standard research stack is 100 mcg CJC-1295 (no DAC) with 200–300 mcg ipamorelin, administered 2–3 times daily in a fasted state.